Clinical Trial Update: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial of trilaciclib in combination with gemcitabine and carboplatin in metastatic triple-negative breast cancer was terminated; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Triple-Negative Breast Neoplasms, Breast Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2022-03-23